Epidemiological evidence suggests a relationship between chronic inflammation and lung cancer. Inflammation in the lung may be modulated by host genetic factors such as polymorphisms in inflammatory genes. Identification of polymorphisms in inflammatory genes may help understanding interindividual differences in susceptibility to lung cancer. We have investigated singlenucleotide polymorphisms (SNPs) and their haplotypes in the regulatory region of the IL1B gene in association to non-small cell lung cancer (NSCLC) risk. Our previous work showed that two promoter SNPs C-511T and T-31C modulated NSCLC risk. In the present study, we show that G-3893A and G-1464C located in the enhancer region of the IL1B gene may also affect this risk, with odds for developing NSCLC being 0.69 [95% confidence interval (CI), 0.52-0.92] for -3893 A-allele and 0.63 (95% CI, 0.47 -0.83) for -1464 C-allele. The associations were particularly prominent in patients with TP53 mutations in the tumor. Inference of the haplotype structures showed that -3893 G, -1464 G, -511 C and -31 T formed a specific haplotype (GGCT) with near complete linkage disequilibrium in lung cancer patients but not in controls. Furthermore, the risk haplotype (GGCT) was present in 65% of cases compared with 36% of controls. Quantitative analysis of RNA in normal lung tissue of the patients showed that the risk haplotype was correlated with significantly higher IL1B messenger RNA (mRNA) levels compared with the non-risk haplotype (ACTC). These data suggest that a specific IL1B haplotype associated with increased IL1B gene expression increases the risk of NSCLC.
Introduction
Lung cancer is the leading cause of cancer mortality worldwide and tobacco smoking is well established as the prime cause of lung cancer (1) . Pulmonary inflammation together with chemical exposure may potentiate the carcinogenic process, underlining the importance of inflammation in lung cancer development (2) (3) (4) (5) . Interleukin-1beta (IL1b), a key proinflammatory cytokine encoded by the IL1B gene, has been associated with chronic inflammation and plays an important role in lung inflammatory diseases, including lung cancer (2, 6, 7) . Elevated levels of IL1-proteins, in particular IL-1b, will greatly enhance the intensity of the inflammatory response. The amount of IL-1b secreted to the microenvironment is regulated at messenger RNA (mRNA) level, protein level and processing of the pro-IL-1b precursor into active IL1b molecules by the caspase-1 enzyme (8, 9) . The link between IL-1b and cancer has not been fully characterized, but its property to stimulate the tumor microenvironment in favor of increased cell proliferation and tissue angiogenesis has been devoted much attention (10) (11) (12) (13) .
At the gene level, IL1B is highly inducible by proinflammatory stimuli. Its promoter contains a TATA box and the regulatory region also includes enhancer sequences distributed several thousand base pairs upstream from the transcription start site. IL1B expression has been shown to be regulated by transcription factors such as CCAAT/ enhancer-binding protein b (C/EBPb), cAMP responsive element binding protein, nuclear factor kappaB and Spi/PU.1 that bind to different regulatory sites (14) . There are large interindividual differences in IL1B expression, which may be explained genetically by several single-nucleotide polymorphisms (SNPs) scattered in its long regulatory region. These polymorphisms may affect IL1B expression by changing affinity for transcription factor binding or creating new binding sites for other transcription factors. The SNPs may also interact with each other forming various haplotype structures. Several studies have implied that studying SNPs as haplotypes rather than individual SNPs may better explain the interindividual differences in IL1B expression (15, 16) .
Sustained inflammatory responses create a microenvironment activating a large number of cytokine and growth factor-secreting cells. Inflammatory cells in such an environment will provide a constant supply of reactive oxygen and nitrogen species. Reactive oxygen/ nitrogen species may react with DNA, causing DNA damage and mutations in critical genes such as TP53 (17, 18) , which are common and early events in lung carcinogenesis. Several studies have shown a link between inflammation and increased burden of TP53 mutations in certain inflammatory diseases (19, 20) . It has been proposed that inducible nitric oxide synthase, which is a downstream target enzyme in the IL-1b-signaling pathway, may contribute to the formation of mutations in the TP53 gene (21) . Furthermore, risk genotypes of SNPs in the IL1B gene have previously been associated with TP53 mutations in non-small cell lung cancer (NSCLC) patients (22) .
The epidemiological evidence suggesting a relationship between chronic inflammation and lung cancer has directed attention to study polymorphisms in inflammatory genes including IL1B (5,23). Several SNPs (C-511T, T-31C and C3954T) in the IL1B gene have been shown to modulate NSCLC risk. Further investigation is needed to elucidate molecular mechanisms explaining the effect of different SNPs and their haplotypes. We analyzed the risk of NSCLC associated with the following SNPs: G-3893A, C-3737T, G-1464C and C3954T in a Norwegian case-control study and the haplotypes were evaluated by analyzing linkage disequilibrium (LD) in cases and controls. Our analysis identified a specific haplotype that was only present in the patients and was associated with a higher level of IL1B mRNA in the lung. We also found a correlation between the risk genotypes and TP53 mutations in the tumors.
Materials and methods
Case-control study The characteristics of lung cancer patients and healthy controls included in the present study are summarized in Table I . A total of 455 lung cancer patients were treated by surgery at the university hospitals in Oslo or Bergen between years 1986 and 2001. Diagnosis of lung cancer was confirmed by two pathologists and patients were enrolled in the study consecutively whenever practically feasible. Less than 5% of the patients declined to participate in the project resulting in an overall response rate of .95% among the patients asked to participate in the study. Further, 11 cases were excluded from the study because of location of primary tumors in other organs. Controls were recruited from a general health survey conducted by the National Health Surveys in the Oslo area (HUBRO) of the general population. The purpose of the surveys was to monitor the health status of the general population. A total of 8100 persons participating in the year 2000-2001 HUBRO study were asked to participate in the present study, and $50% of the subjects contacted agreed to be included in the control group. Among them, 440 current or ex-smokers without any known history of cancer were randomly selected and frequency matched with the cases on age, smoking dose (pack-years) and male:female ratio. Cases and controls were interviewed by trained health personnel using questionnaires containing comparable information on demographic and lifestyle details. All subjects were informed about the project and gave written consent to participate in the study and to allow their biological samples to be genetically analyzed. The study was conducted in accordance with guidelines set up by the Regional Ethical Committee and the Data Inspectorate of Norway.
DNA extraction, genotyping and SNP selection DNA was extracted from biological samples (blood or frozen tissue) either with DNA isolation kits (Qiagen, Hilden, Germany) or standard proteinase K digestion followed by phenol-chloroform extraction and ethanol precipitation. DNA from cases and controls was randomized and mixed on polymerase chain reaction (PCR) plates in order to ensure that an equal number of cases and controls could be analyzed simultaneously. The SNPs analyzed were tag SNPs (www.hapmap.org, HapMap generic genome browser version 1.69, Data Rel 23a, dbSNPb126) and were chosen on the basis of either being functional (16) , increasing cancer risk (24, 25) or relevantly situated in relation to the SNPs studied. The C-3737T (rs4848306), G-1464C (rs1143623) and C3954T (rs1143634) SNPs have previously been reported to be functional (16, 26) , whereas G-3893A (rs12621220) has not been analyzed in either association or functional studies. Genotyping of IL1B G-3893A, C-3737T, G-1464C and C3954T were carried out using pre-designed or custom TaqMan assays (Applied Biosystems, Foster City, CA) according to the manufacturer's recommendations. Approximately 10 ng genomic DNA was amplified in 5 ll reaction mixture in a 384-well plate containing 1Â universal TaqMan master mix and 1Â assay mix containing a premix of the respective primers and MGBprobes labeled either with FAM or VIC. After initial denaturation and enzyme activation at 95°C for 10 min, the reaction mixture was subjected to 40 cycles of 95°C for 15 s and 60°C for 1 min. The reactions were performed on an ABI 7900HT sequence detection system. Equal numbers of cases and controls were run simultaneously, and negative controls containing water instead of DNA were included in every run. Genotypes were determined in the SDS 2.2 software (Applied Biosystems). Approximately 10% of the samples were regenotyped and the concordance rate was 100%. The number of successfully genotyped cases and controls for different SNPs varies and may be affected by the sequence context surrounding each SNP.
Haplotype frequencies and LD analysis
Haplotype frequency estimations were performed by the use of PHASE version 2.1 as described by Stephens et al. (27, 28) . To make the genotype data available for PHASE, the input was transformed through a Microsoft Excel macro developed by Cox et al. (29) . The frequencies were assessed for calculation of D# and r 2 values as well as LD-contrast test. D# and r 2 values were calculated from a Microsoft Excel macro kindly provided by Dr David Cox and is available upon request.
Determination of mRNA levels by quantitative real-time PCR
The levels of mRNA were measured by quantitative real-time PCR (qPCR). Total RNA was extracted from frozen, crushed normal lung tissue by the TRIzol reagent (Invitrogen, Paisley, UK) and reverse transcribed using random primers (Roche Molecular Biochemicals, Basel, Switzerland). B-actin (ACTB) was used as a reference gene; the PCR amplicons were designed over introns to avoid the amplification of possible traces of genomic DNA contamination (Primer Express 2.0 software, Applied Biosystems), primers for ACTB has been published previously (30) . IL1B primers were pre-designed (Qiagen) and used according to the manufacturer's recommendations. PCR was performed on an ABI 7900HT sequence detection system (Applied Biosystems) with SYBR Green I. After initial denaturation at 95°C for 10 min, the reaction mixtures were subjected to 40 cycles of 95°C for 15 s and 60°C for 1 min, followed by one cycle of 95°C for 15 s, 60°C for 15 s and 95°C for 15 s for melting curve analyses. The internal standard, a known amount of PCR-product for IL1B and ACTB, was used in dilution series as template in the real-time PCR and served as a control of successful PCR and for estimating target complementary DNA quantity. Specific gene expression levels were normalized to the expression of ACTB and calculated by the standard curve method.
Analysis of TP53 mutations in tumor tissues
Tumor tissues obtained from lung cancer patients at time of surgery were kept frozen at À80°C and DNA was extracted from the tissue using standard proteinase K digestion followed by phenol-chloroform extraction and ethanol precipitation. Tumor DNA was screened either by single strand conformation polymorphism or denaturating gradient capillary electrophoresis, covering the exons 4-9 of the TP53 gene as described (31) . Mutated exons were sequenced either by direct sequencing using BigDye chemistry (Applied Biosystems) or by the use of an arrayed primer extension platform (32, 33) . The efficiency of the two methods in detecting mutations was similar, being 54% for the APEX and 52% for the BigDye chemistry. Primers and conditions used in PCR reactions and sequencing are available upon request.
Bioinformatic analyses of putative transcription factor binding A short sequence surrounding the different SNPs was evaluated for the presence of putative-binding sites of known transcription factors. The binding sites were assessed by the means of PROMO version 3.0.2 database (34,35), using the TRANSFAC version 8.3, with a cutoff for the dissimilarity matrix at 5%. The random expectation values are measure of the reliability of the different predictions, the expectation of finding each of the matches, in a random sequence of 1000 nucleotides, considering both a model with equiprobability of the four nucleotides and a model with the same nucleotide frequency as the query sequence.
Statistical methods Determination of differences in demographic variables and calculation of odds ratios Differences in demographic variables, smoking and grouped genotypic frequencies between the cases and control subjects were evaluated by using the chi-square test. All reported P-values are two sided with P , 0.05 considered as significant. Hardy-Weinberg equilibrium was estimated in controls for each polymorphism with P 5 0.05 as the threshold. The association between the variant genotypes and risk of lung cancer was estimated by computing odds ratios (ORs) and their 95% confidence intervals (CIs) from unconditional logistic regression analyses. When appropriate, age, sex and cumulative smoking dose (pack-years) were used as covariates. Generally, homozygosity for the more frequent allele among controls was set as the reference group. For the genotypes in relation to TP53 mutations, the risk allele was set as the reference. The quantitative measurement of IL1B mRNA from normal lung tissue were compared by the non-parametric Mann-Whitney test for independent samples. P , 0.05 was chosen for cutoff levels for statistical significance. All statistical analyses were performed using the SPSS (version 15.0) statistical package.
The LD-contrast test LD differences in cases and controls were analyzed by the LD-contrast test as described by Zaykin et al. (36) that presented a script written for the statistical language R (www.r-project.org). In brief, the method tested for a difference between cases and controls with respect to pairwise LD between two haplotype markers. The method returned a statistical value in order to identify differences between cases and controls. For each execution of the script, 200.000 permutations were included for both the 'dprime' and 
The plot.LD test Kulle et al. has previously developed tools for LD analyses in R, including a tool for visualization of LD data from two sources (37) . The original script 'plot.LD.r' gives LD data in grayscale and was modified for a plot in colors. The modified script plots LD data in a gradient from zero to one scattered evenly over four colors. The following part of the script was modified 'col.regions 5 gray (100:2/100)' by replacing it with 'col.regions 5 colorRampPalette[c(''white'',''blue'',''purple'',''red'')],cut 5 1000'. We produced a visual presentation of LD data from PHASE as SNP 1-4 for controls on the y-axis and SNP 1-4 for cases on the x-axis in the specified color scheme.
Multiple testing and false-positive rates To evaluate the chance of obtaining a false-positive association in our dataset, two tests were used: the false-positive report probability (FPRP) was calculated as described by Wacholder et al. (38) and the Bayesian false-discovery probability (BFDP) test described by Wakefield et al. (39) . Both methods rely on the decision of a prior probability level to indicate whether a test is considered noteworthy or not. Three levels of prior probability for SNP analysis have been suggested: (i) prior probability 0.1 when a strong biological plausibility consistent with epidemiological evidence exist, (ii) prior probability 0.01 when either biological knowledge or epidemiological data is missing and (iii) prior probability 0.001 when no biological or epidemiological data are present or inadequate (40) . In this paper, we chose to include an intermediate level at 0.025 since sufficient evidence for biological relevance for the SNPs in the IL1B gene exists (16, 22, 24) . The a priori OR was set at 1.5, and the selected levels of noteworthiness for FPRP and BFDP at 0.2 and 0.8, respectively, as recommended in the original papers (38, 39) .
Results
The relevant characteristics of the study subjects are shown in Table I . Cases and controls were similar in terms of gender distribution and smoking habits and all were smokers. Genotypes were obtained for .90% of cases and controls for all four SNPs (Table II) ; hence, there was no evidence of any systematic bias in genotyping. The SNPs were in Hardy-Weinberg equilibrium in cases and controls with nonsignificant P-values (P . 0.05).
Association of the individual SNPs with risk of NSCLC
The IL1B -3893 A-allele and -1464 C-allele were associated with reduced risk of NSCLC with OR of 0.69 (95% CI, 0.52-0.92) and 0.63 (95% CI, 0.47-0.83), respectively (Table II) . The associations of -3893 A-allele and -1464 C-allele were found noteworthy by both the FPRP and BFDP tests. Further analyses of the SNPs revealed that the risk were particularly apparent in the cases with squamous cell carcinoma OR of 0.59 (95% CI, 0.40-0.87; P 5 0.008) for -3893 A and 0.47 (95% CI, 0.32-0.69; P , 0.001) for -1464 C (supplementary Table SI is available at Carcinogenesis Online), respectively. There was no significant relationship between the IL1B SNPs C-3737T and C3954T and NSCLC.
Interaction between polymorphisms and TP53 mutational status in the tumors There was a correlation between risk of NSCLC, the risk genotypes and having a TP53 mutation in the tumor. Notably, individuals with -3893 G or -1464 G-alleles had a higher frequency of TP53 mutations compared with the cases with the non-risk alleles. Using the non-risk allele as the reference, the ORs were 3.02 (95% CI, 1.13-8.08; P 5 0.023) for -3893 G and 3.18 (95% CI, 1.22-8.29; P 5 0.015) for -1464 G (Table III) . Detailed evaluation of the mutational pattern in tumors showed trends toward higher frequencies of insertions or deletions in cases with the risk alleles, where 68.2% of cases with -3893 G or -1464 G had insertions/deletions.
A specific risk haplotype is common in cancer patients
We constructed haplotypes structures and estimated the degree of LD between the SNPs that were associated with NSCLC risk (G-3893A and G-1464C), including two other SNPs in the promoter region of the IL1B gene (C-511T and T-31C). The haplotypes and their frequencies were different in cases and controls. In the controls, 10 haplotypes were found compared with four haplotypes in the cases (Table IV) . Interestingly, the risk haplotype (GGCT) constitutes 36% in the controls compared with 65% in the cases, whereas the frequency of the non-risk haplotypes (G/ACTC) was 23% in controls and 26% in cases, respectively ( Figure 1A ). To further evaluate the linkage of these SNPs, we used a macro based on the data obtained from haplotype analysis and calculated D# and r 2 values ( Figure 1B ). The C-511T and T-31C SNPs were almost in complete LD both in controls (D# 5 0.91) and cases (D# 5 0.98). The G-1464C SNP was partially linked in controls with a D# of 0.57 compared with 0.99 in cases. The G-3893A SNP was not linked to any of the other SNPs in the controls; however, we observed that both G-3893A and G-1464C were almost in complete LD with other SNPs in the cases ( Figure 1B) . The differences in LD between the cases and controls were determined by using the LD-contrast test (36) . LD-contrast test confirmed our results, when assessing 200.000 permutations the P-value was highly significant (P , 0.001, data not shown). Figure 1C depicts a heatmap displaying the differences in LD in the controls and cases.
The risk genotypes and haplotypes are associated with increased IL1B mRNA levels in normal lung We performed qPCR on RNA isolated from normal lung tissue of 48 lung cancer patients. High levels of IL1B mRNA were significantly associated with -3893 G/G or -1464 G/G (Figure 2A) . The IL1B expression data were also analyzed in regard to C-511T and T-31C that have been shown to be functional promoter SNPs. Individuals with -511 C/C or -31 T/T expressed significantly higher IL1B mRNA levels compared with the -511 T/T or -31 C/C, respectively (Figure 2A) . The homozygote genotypes of the SNPs that were not associated with lung cancer risk did not correlate with IL1B mRNA expression.
Since the SNPs were in strong LD in the cases, we also investigated the expression of IL1B in relation to the risk and non-risk haplotypes.
Results showed that the risk haplotype (GGCT) had a significantly higher expression of IL1B mRNA compared with the non-risk ACTC haplotype ( Figure 2B ).
Bioinformatic investigation of transcription factor binding to SNP sites Investigation of putative transcription factor binding sites for each SNP was performed by using PROMO database (supplementary Table  SII is available at Carcinogenesis Online). The -3893 G-allele showed binding sites for c-E26 transformation-specific-1 (c-Ets-1) and Elk-1. A potential binding site for c-Ets-1 is also present in -3893 A; however, -3893 A shared the strongest similarity with TFII-I. Both G and C-alleles of -1464 SNP share similarity with C/EBPb, but with higher dissimilarity in -1464 G. The -1464 G-allele also contained possible binding sites for GATA-1 and GATA-2. C-511T contained a similarity IL1B haplotypes in lung cancer with the activator protein-2 alpha. The binding sites for T-31C showed that when a T is replaced by a C the TATA-binding protein and transcription factor TFIID can no longer bind but creating a new binding site for the transcription factor Yin Yang 1.
Discussion
An elevated inflammatory response to tobacco-induced lung damage may contribute to carcinogenesis. IL-1b, a proinflammatory cytokine important in initiating and balancing the level of inflammatory response, plays an important role in various lung diseases such as chronic obstructive pulmonary disease (COPD) and lung cancer. The property of IL-1b as a potent inducer of inflammation makes it an interesting candidate for lung cancer susceptibility (5, 41) .
In the present study, we have investigated SNPs in the IL1B gene and if these SNPs affect expression of the gene in the lung and NSCLC risk. We have focused on surgical NSCLC cases, thus the inferences that are drawn may not be appropriate for more severe or non-surgical lung cancer cases. Overall, we found statistically significant effects on NSCLC in association with -3893 G and -1464 G-alleles, which were further strengthened, as the SNPs were found noteworthy by both the FPRP and BFDP tests. The -1464 G-allele has previously been associated with an increased risk of gastric cancer (25) , but these polymorphisms as disease determinants have given variable results (42) . The C-3737T and C3954T SNPs have been associated with COPD and lung cancer, respectively (24, 42) , but did not show any associations with NSCLC in the present study.
With our moderate sample size of 895 subjects (initially 455 cases and 440 controls), we had .80% power of detecting an OR .1.5 for SNPs with minor allele frequency of .28%. Only the C3954T SNP had a minor allele frequency below this threshold. However, even with larger sample sizes there have been no main effects of this SNP on NSCLC susceptibility (43) .
Our data showed an association between the risk alleles -3893 G and -1464 G and TP53 mutations in the tumor. The mutational pattern showed a trend toward insertions or deletions that are specific types of mutations often detected in cancers with a strong inflammatory component (44, 45) . Cigarette smoke contains a complex mixture of compounds that produces an inflammatory stress response, creating a lung environment with constant supply of tumor initiators and promoters (46) . Recently, the role of IL-1b in chemical carcinogen-induced tumors was demonstrated by Krelin et al. (41) , by exposing Balb/c IL-1b knockout mice with the complete carcinogen 3-methylcholanthrene. The experimental data showed that IL-1b played a crucial role in tumor development, invasiveness and infiltration of inflammatory cells at the exposure site. Mediators of inflammation that are increased upon stimulation with IL-1b, such as NO Á , have been shown to exhibit promutagenic functions, giving rise to TP53 mutations. Polymorphisms that increase IL1B expression may influence the level of reactive oxygen and nitrogen species in the lung epithelial microenvironment generating an environment for induction of N.E. Landvik et al. mutations in tumor suppressor genes such as TP53 through inflammatory-mediated mechanisms (19) .
The haplotype analyses on estimated LD (D#) of the risk SNPs (G-3893A and G-1464C) and previously studied C-511T and T-31C (22) showed that these SNPs formed a specific haplotype in the cases but not in the controls. Previous haplotype studies have shown that G-1464C, C-511T and T-31C are in LD. Rogus et al. (15) reported that a haplotype containing C-3737T, G-1464C and C-511T was associated with higher levels of IL-1b in gingival fluid, especially when -1464 G and -511 C-alleles were present. This is in agreement with our findings where a disease-related haplotype, including -1464 G, -511 C and -31 T, had higher IL1B expression in the lungs compared with the non-risk haplotype (-1464 C, -511 T and -31 C). We also found that G-3893A as a part of this haplotype or alone may affect IL1B expression. The T-31C has been of particular interest since the C-SNP will disrupt the TATA box and is thus believed to affect transcription. Indeed, the experimental data show that the IL1B promoter with a T in this position has higher transcriptional activity (47) and when stimulated with lipopolysaccharide resulted in increased transcription factor binding compared with the C-SNP (48) . On the other hand, the C-SNP creates a new binding site for transcription factor Yin Yang 1, which can regulate transcription either as an activator or repressor, depending on which cofactor is recruited (49) . Increased levels of secreted IL-1b may be due to transcriptional activation of the gene, increased stability of its mRNA and/or activating cleavage of its proprotein form (14) . It would therefore be interesting to examine if the increased level of IL1B mRNA also reflects the level of active secreted IL-1b.
Using established transcription factor databases and bioinformatics tools, we searched for changes in transcription binding patterns as a result of base changes at the SNP sites. It was found that the G-1464C had a putative C/EBPb-binding site with the highest binding affinity for -1464 C compared with G, which is in agreement with electrophoretic mobility shift assay results (16, 25) . C/EBPb is known to bind to the IL1B gene regulatory region affecting its transcription (14) . We also show that IL1B expression in normal lung tissue was higher in cases carrying -1464 G compared with the C-allele, also seen for different tissues in other studies (15, 16) . C/ EBPb has been shown to interact with the transcription factor cAMP responsive element binding protein and SMAD3/4, conducting inhibitory effects on transcription (50, 51) and may be the cause of the reduced IL1B expression that is seen for -1464 C. For the -3893 SNP, the general transcription factor TFII-I showed higher affinity for -3893 A. TFII-I may bind to enhancer regions and may associate with histone deacetylase-3 that is linked to repression of gene expression (52) . The sequences surrounding -3893 G had a putative binding site for the Ets family member Elk-1, which is known to activate transcription upon stimulation from the mitogen-activated protein kinase-signaling pathway. Members of this family have been shown to activate transcription of IL1B and their activation is often associated with increased proliferation and cell survival (53) . Although the IL1B SNPs may upregulate the IL1B mRNA and the pro-IL-1b protein levels, the level of secreted IL-1b will also depend on the enzymatic cleavage of the pro-IL-1b precursor by caspase-1 activity. The IL1B-coding C3954T SNP is situated in close proximity to where caspase-1 cleaves pro-IL-1b. There are no published studies describing IL1B-coding SNPs that functionally have been validated to alter IL-1b cleavage by caspase-1. Further, functional analyses of the SNPs in this novel disease-related haplotype are needed and are currently being investigated in our laboratory to elucidate which transcription factors are responsible for their differential effects on IL1B expression.
In conclusion, our data show an association between SNPs in the IL1B gene regulatory region and risk of NSCLC. The association was particularly prominent in patients with TP53 mutations in the tumor. We also provide evidence that the risk SNPs are in strong LD in the cases but not in the controls. Further, we have identified a lung cancer risk haplotype that results in increased expression of IL1B in normal lung tissue of the patients. These data suggest that a specific haplotype in the IL1B regulatory region provide a microenvironment with elevated inflammatory stimuli that may be further enhanced by cigarette components and thus increasing the risk for NSCLC.
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